World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |

Journal website http://www.wjon.org |

Original Article

Volume 2, Number 1, February 2011, pages 1-9

**Radiosensitivity and Capacity to Recover from Radiation-Induced Damage in Pimonidazole-Unlabeled Intratumor Quiescent Cells Depend on p53 Status**

Figures

Tables

Total tumor cells | Quiescent cells | |
---|---|---|

a): Mean ± standard error (n = 9) | ||

SAS/neo | ||

Plating efficiency (%) | 45.5 ± 8.9^{a)} | |

Micronucleus frequency | 0.038 ± 0.006 | 0.056 ± 0.007 |

Apoptosis frequency | 0.083 ± 0.008 | 0.106 ± 0.015 |

Especially in pimonidazole unlabeled cell fraction | 0.045 ± 0.005 | 0.058 ± 0.008 |

SAS/mp53 | ||

Plating efficiency (%) | 23.5 ± 4.1 | |

Micronucleus frequency | 0.072 ± 0.008 | 0.111 ± 0.010 |

Apoptosis frequency | 0.021 ± 0.003 | 0.033 ± 0.004 |

Especially in pimonidazole unlabeled cell fraction | 0.011 ± 0.001 | 0.019 ± 0.003 |

High dose-rate Immediately after | High dose-rate 24 hours after | Reduced dose-rate | |
---|---|---|---|

a): The ratio of the dose of radiation necessary to obtain the normalized apoptosis frequency of 0.05 in a whole cell fraction to that needed to obtain the frequency in the pimonidazole unlabeled cell fraction. | |||

b): Mean ± standard error (n = 9) | |||

SAS/neo | |||

Total cell population | 1.45 ± 0.15^{b)} | 1.45 ± 0.15 | 1.45 ± 0.15 |

Quiescent cell population | 1.6 ± 0.2 | 1.55 ± 0.15 | 1.55 ± 0.15 |

SAS/mp53 | |||

Total cell population | 1.5 ± 0.15 | 1.5 ± 0.15 | 1.5 ± 0.15 |

Quiescent cell population | 1.8 ± 0.25 | 1.75 ± 0.2 | 1.7 ± 0.2 |

High dose-rate 24 hours after | Reduced dose-rate | |
---|---|---|

a): The ratio of the dose of radiation necessary to obtain each end-point with a delayed assay or reduced dose-rate irradiation to that needed to obtain each end-point with an assay immediately after high dose-rate irradiation. | ||

b): Mean ± standard error (n = 9) | ||

SAS/neo | ||

Surviving fraction = 0.2 | ||

Total cells | 1.1 ± 0.05^{b)} | 1.2 ± 0.1 |

Normalized micronucleus frequency = 0.1 | ||

Total cells | 1.15 ± 0.05 | 1.25 ± 0.1 |

Quiescent cells | 1.3 ± 0.1 | 1.6 ± 0.2 |

Normalized apoptosis frequency = 0.05 | ||

Total cells | 1.15 ± 0.05 | 1.25 ± 0.1 |

Especially in pimonidazole unlabeled cell fraction | 1.15 ± 0.05 | 1.3 ± 0.1 |

Quiescent cells | 1.2 ± 0.1 | 1.4 ± 0.15 |

Especially in pimonidazole unlabeled cell fraction | 1.35 ± 0.15 | 1.6 ± 0.2 |

SAS/mp53 | ||

Surviving fraction = 0.2 | ||

Total cells | 1.05 ± 0.05 | 1.1 ± 0.05 |

Normalized micronucleus frequency = 0.1 | ||

Total cells | 1.05 ± 0.05 | 1.1 ± 0.05 |

Quiescent cells | 1.1 ± 0.05 | 1.15 ± 0.05 |

Normalized apoptosis frequency = 0.05> | ||

Total cells | 1.1 ± 0.05 | 1.15 ± 0.05 |

Especially in pimonidazole unlabeled cell fraction | 1.15 ± 0.05 | 1.2 ± 0.1 |

Quiescent cells | 1.15 ± 0.05 | 1.2 ± 0.1 |

Especially in pimonidazole unlabeled cell fraction | 1.25 ± 0.1 | 1.3 ± 0.1 |

High dose-rate Immediately after | High dose-rate 24 hours after | Reduced dose-rate | |
---|---|---|---|

a): The ratio of the dose of radiation necessary to obtain each end-point in the quiescent cell population to that needed to obtain each end-point in the total tumor cell population. | |||

b): Mean ± standard error (n = 9) | |||

SAS/neo | |||

Normalized micronucleus frequency = 0.1 | 2.0 ± 0.2^{b)} | 2.35 ± 0.2 | 2.65 ± 0.25 |

Normalized apoptosis frequency = 0.05 | 1.7 ± 0.15 | 1.75 ± 0.2 | 1.85 ± 0.2 |

Especially in pimonidazole unlabeled cell fraction | 1.55 ± 0.1 | 1.6 ± 0.15 | 1.65 ± 0.15 |

SAS/mp53 | |||

Normalized micronucleus frequency = 0.1 | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.85 ± 0.2 |

Normalized apoptosis frequency = 0.05 | 1.65 ± 0.15 | 1.7 ± 0.15 | 1.75 ± 0.2 |

Especially in pimonidazole unlabeled cell fraction | 1.5 ± 0.1 | 1.55 ± 0.1 | 1.6 ± 0.15 |